Date:
Wed, 29 Apr 2026 09:54:55 EDT
Content:
The U.S. Food and Drug Administration (FDA) has published a Form 483 following an inspection of EUGIA Pharma Specialities Limited’s facility in India. The document outlines observations made by investigators during an inspection completed in February 2026.
A Form 483 is issued when FDA investigators observe conditions that may constitute violations of the Food, Drug, and Cosmetic Act. These observations typically involve concerns regarding manufacturing processes, quality control, or facility maintenance that could impact the safety and efficacy of pharmaceutical products.
Following the issuance of these findings, the company is expected to respond with a comprehensive corrective action plan to address the highlighted deficiencies. The FDA will then evaluate the response to determine if the proposed measures are sufficient to bring the facility into compliance with current Good Manufacturing Practices (cGMP).
Source: FDA CDER FOIA Electronic Reading Room
Link:
http://www.fda.gov/drugs/cder-foia-electronic-reading-room/eugia-pharma-specialities-limited-2272026
Keywords:
FDA, EUGIA Pharma Specialities Limited, Form 483, Pharmaceutical Inspection, India, cGMP Compliance